Acute leukemia. Acute leukemia of unspecified cell type
Conditions
Interventions
Intervention 1: Intervention group: Acute leukemia patients receive T cell repleted hematopoietic stem cell transplantation from a haplotype donor with cyclophosphamide (Ptcy) and then modified DLI
Sponsors
Shahid Beheshti University of Medical Sciences
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Transplantation of T cell replete haplotype with cyclophosphamide The estimated life expectancy more than one year Karnofsky index above 70%
Exclusion criteria
Exclusion criteria: GVHD of grade 2 or less Uncontrolled bacterial infection Insufficient intake: WBC<2500/mm3 and Platelet<50000/mm3 Evidence of recurrence Concomitant treatment with corticosteroids and/or other immunosuppressive drugs Infection with hepatitis B, C and HIV pathogens
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infection rate after treatment with modified DLI. Timepoint: From the first dose of modified DLI infusion until one year after its last dose on days 90, 180, and 360. Method of measurement: Examining clinical symptoms, performing laboratory tests for viral infections, performing laboratory tests for bacterial and fungal infections in case of clinical symptoms. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of "Overall survival" in a one year period. Timepoint: From the first dose of modified DLI infusion until one year after its last dose. Method of measurement: Regular patient visits to bone marrow transplantation clinic for follow-up and regular telephone monitoring of patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElham Roshandel
Shahid Beheshti University of Medical Sciences
Outcome results
None listed